Scientific Research Publishing

Post-Traumatic Tracheal Tear in a Child: Conservative Management of a Case at the Kolda Regional Hospital Center ()

The cervicothoracic CT scan revealed an anterior tracheal breach of 2 mm at the level of the C5 vertebral body, complicated ...

Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny

While federal officials say they intend to crack down on misleading drug ads, cosmetic surgery remains a “buyer beware” ...

Ads promising patients a ‘dream body’ with minimal risk get little scrutiny

State and federal authorities have the power to prohibit false or misleading medical advertising, though enforcement is ...
Medical Marketing & Media

Advertisements promising patients a ‘dream body’ with minimal risk get little scrutiny

State and federal authorities do have the power to prohibit false or misleading medical advertising of all types, though ...
casereports.bmj

Spontaneous pneumomediastinum with extensive subcutaneous emphysema secondary to upper respiratory tract infection

Examination revealed subcutaneous crepitus, and CT confirmed pneumomediastinum with extensive subcutaneous emphysema. She was managed conservatively with high-flow oxygen, analgesia and antibiotics, ...
casereports.bmj

Spontaneous pneumomediastinum with extensive subcutaneous emphysema secondary to upper respiratory tract infection

We will not keep your email address; we ask for it so your friend knows the email isn't spam.
pharmaphorum

MSD says subcutaneous Keytruda matches IV form

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings. The new ...
The American Journal of Managed Care

FDA Approval of Subcutaneous Amivantamab Offers Faster, Safer Option for EGFR-Mutated NSCLC

Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...
pharmaphorum

FDA clears subcutaneous Keytruda in a boost to MSD

MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...